| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 100.1 | 77.4 | 81.9 |
| Other income | -3.0 | 0.7 | -7.0 |
| Total income | 97.1 | 78.1 | 75.0 |
| Profit before exceptional items & tax | 22.2 | 13.5 | 3.7 |
| Exceptional items | 2.9 | 0.0 | 0.0 |
| Profit before tax | 25.1 | 13.5 | 3.7 |
| Net profit | 16.5 | 9.3 | 1.5 |
| Operating margin | 25.8% | 17.3% | 4.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1000.00% |
|---|---|
| Net profit, quarter on quarter | +77.40% |
| Revenue, year on year | +22.20% |
BSE results filing, NSE: HESTERBIO. Figures extracted from the filing.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,165.30
- Market cap
- ₹1,842 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.5×Sector 47.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Credit Rating
Hester Biosciences Ltd received an upgrade in its long-term and short-term bank facility credit ratings from CARE Ratings.
Hester Biosciences Annual General Meeting
Hester Biosciences is conducting a postal ballot to seek shareholder approval for the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public'.
Hester Biosciences Other Announcement
Hester Biosciences Limited has launched a dedicated interactive digital microsite for its 39th Annual Report for FY 2025-26 to enhance stakeholder accessibility and engagement.
Hester Biosciences Earnings Call Transcript: Key Takeaways
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.